Not surprisingly, people who have Type 2 diabetes, as well as those with higher incomes and fewer side effects, are more likely to stay on GLP-1s
Always up for a chat, she believes the best stories come from unfiltered yapping, where "too much information" is kind of the point
Once the patient stabilizes, monitoring intensity can decrease or conclude entirely
Oral GLP-1 RA are under development to improve convenience, acceptance, and adherence and may provide an additional option to support obesity management
Double-blinded trial providing evidence that once-weekly semaglutide could achieve weight loss in participants with obesity, which can lead to insulin resistance and type 2 DM
Yes, but only when prepared by a licensed or certified pharmacy specializing in compounding